【私募调研记录】勤远投资调研盟科药业

Group 1 - The core viewpoint of the article highlights that Qinyuan Investment has conducted research on a listed company, Amgen Pharmaceuticals, which has significant advancements in the field of antibiotic resistance [1] - Amgen Pharmaceuticals has successfully developed a new generation antibiotic, Contizole Tablets, and is advancing several other drugs, including MRX-4, MRX-8, and MRX-5, through clinical trials [1] - MRX-5, a novel benzoborazole antibiotic, has completed Phase I clinical trials in Australia, demonstrating good safety and tolerability [1] - MRX-8, a new polymyxin antibiotic, has completed Phase I clinical trials in both China and the United States [1] - In Q1 2025, Amgen Pharmaceuticals reported revenue of 33,216,965.04 yuan, a year-on-year increase of 0.61%, with reduced losses attributed to cost control measures [1] - Research and development expenses decreased by 36.38% year-on-year due to the completion of certain ongoing projects [1]